Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31256059 | 0.84 | NOS3 (0.44) | NOS3NOS1NOS2MAOBMAOA | |
| SCHEMBL16897461 | 0.84 | NOS3 (0.44) | NOS3NOS1NOS2MAOBMAOA | |
| SCHEMBL29529036 | 0.83 | MPO (0.40) | NOS3NOS1NOS2MAOBMAOA | |
| SCHEMBL365958 | 0.83 | MPO (0.40) | NOS3NOS1NOS2MAOBMAOA | |
| SCHEMBL30683036 | 0.82 | NOS3 (0.46) | NOS3NOS1NOS2MAOBMAOA | |
| SCHEMBL1366457 | 0.82 | NOS3 (0.49) | NOS3NOS1NOS2MAOBMAOA | |
| SCHEMBL1519547 | 0.82 | CSNK2A1 (0.49) | NOS3NOS1NOS2MAOBMAOA | |
| SCHEMBL12317793 | 0.82 | NOS3 (0.46) | NOS3NOS1NOS2MAOBMAOA | |
| SCHEMBL16955085 | 0.82 | NOS3 (0.46) | NOS3NOS1NOS2MAOBMAOA | |
| SCHEMBL27552968 | 0.79 | GSK3B (0.37) | NOS3NOS1NOS2MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2025-02-06 | — | — | US | disclosed |
| CN-119019417-A | Pyrazole five-membered ring macrocyclic derivative and preparation method and application thereof | 山东绿叶制药有限公司 | 2024-11-26 | — | — | CN | disclosed |
| US-20240368133-A1 | Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling | CONFO THERAPEUTICS N.V. (BE) | 2024-11-07 | — | — | US | disclosed |
| EP-4428130-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | Ubix Therapeutics, Inc. (KR) | 2024-09-11 | — | — | EP | disclosed |
| CN-118159530-A | Compounds for the treatment of pain, in particular neuropathic pain and/or other diseases or disorders associated with AT2R and/or AT2R mediated signalling | 康福治疗有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118159532-A | Compound with BTK protein degradation activity and medical application thereof | 尤比克斯治疗公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-4377307-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN, IN PARTICULAR NEUROPATHIC PAIN, AND/OR OTHER DISEASES OR DISORDERS THAT ARE ASSOCIATED WITH AT2R AND/OR AT2R MEDIATED SIGNALING | Confo Therapeutics N.V. (BE) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023080732-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | 주식회사 유빅스테라퓨틱스 | 2023-05-11 | — | — | WO | disclosed |
| WO-2023080732-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | 주식회사 유빅스테라퓨틱스 | 2023-05-11 | — | — | WO | disclosed |
| US-11572356-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2007068905-A1 | 1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS | STERIX LIMITED (GB) | 2007-06-21 | — | — | WO | disclosed |
| US-20070117855-A1 | Phenyl-sulfamates as aromatase inhibitors | STERIX LIMITED (GB) | 2007-05-24 | — | — | US | disclosed |
| US-20070117855-A1 | Phenyl-sulfamates as aromatase inhibitors | STERIX LIMITED (GB) | 2007-05-24 | — | — | US | disclosed |
| US-20070117855-A1 | Phenyl-sulfamates as aromatase inhibitors | STERIX LIMITED (GB) | 2007-05-24 | — | — | US | disclosed |
| EP-1753732-A1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | Sterix Limited (GB) | 2007-02-21 | — | — | EP | disclosed |
| EP-1720613-A2 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF 17BETA-HYDROXYSTEROID DEHYDROGERNASE 3 | Bristol-Myers Squibb Company (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005118560-A1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | STERIX LIMITED (GB) | 2005-12-15 | — | — | WO | disclosed |
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-10 | — | — | US | disclosed |
| WO-2005084296-A2 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF 17BETA-HYDROXYSTEROID DEHYDROGERNASE 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-15 | — | — | WO | disclosed |
| WO-2002070469-A2 | SELECTIVE PDE3B INHIBITORS AND USE OF THE SAME IN THERAPY | ICOS CORPORATION (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572356-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | ABL1, BTK, LYN | NOS3 2224/4885NOS1 3378/4885NOS2 3431/4885 |
| US-20070117855-A1 | Phenyl-sulfamates as aromatase inhibitors | CYP19A1, CYP17A1, CYP21A2 | NOS3 71/4885NOS1 74/4885NOS2 86/4885 |
| US-20240368133-A1 | Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling | AGTR2, AGTR1, OPRL1 | NOS3 707/4885NOS1 1045/4885NOS2 924/4885 |
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | BTK, LYN, SYK | NOS3 3104/4885NOS1 3478/4885NOS2 3354/4885 |
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | HSD17B3, HSD17B11, HSD17B1 | NOS3 3602/4885NOS1 4456/4885NOS2 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.